Compare MRVI & LMRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | LMRI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2025 |
| Metric | MRVI | LMRI |
|---|---|---|
| Price | $5.76 | $12.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.13 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 2.0M | 443.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | $6.35 |
| Revenue Next Year | $7.87 | $5.61 |
| P/E Ratio | ★ N/A | $236.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.29 | $6.45 |
| 52 Week High | $7.44 | $19.45 |
| Indicator | MRVI | LMRI |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 58.79 |
| Support Level | $5.54 | $10.09 |
| Resistance Level | $6.55 | $12.93 |
| Average True Range (ATR) | 0.31 | 0.68 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 25.37 | 62.38 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.